Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prophylactic HPV vaccines.

A Szarewski1

  • 1Cancer Research UK, Centre for Epidemiology, Mathematics and Statistics Wolfson Institute of Preventive Medicine, London, UK.

European Journal of Gynaecological Oncology
|July 13, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discussion.

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception·2017
Same author

Comparing the performance of six human papillomavirus tests in a screening population.

British journal of cancer·2013
Same author

Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18.

International journal of cancer·2011
Same author

HPV self-sampling as an alternative strategy in non-attenders for cervical screening - a randomised controlled trial.

British journal of cancer·2011
Same author

Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study.

British journal of cancer·2010
Same author

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.

Lancet (London, England)·2009
Same journal

Timing and duration of bevacizumab treatment and survival in patients with recurrent ovarian, fallopian tube, and peritoneal cancer: a multi-institution study.

European journal of gynaecological oncology·2023
Same journal

Sclerosing stromal tumor of the ovary in a perimenopausal woman: a case report.

European journal of gynaecological oncology·2018
Same journal

Chemotherapy-induced differentiation to cure botryoid rhabdomyosarcoma: a case report and review of the literature.

European journal of gynaecological oncology·2018
Same journal

Mixed endometrial stromal and smooth muscle tumor of the uterus in a postmenopausal woman: morphologic and immunohistochemical features.

European journal of gynaecological oncology·2018
Same journal

Retroperitoneal primitive neuroectodermal tumor (PNET): case report and review of literature.

European journal of gynaecological oncology·2018
Same journal

Advanced stage yolk sac ovarian tumour: clinical approach with cytoreductive surgery upfront.

European journal of gynaecological oncology·2018
See all related articles

Human papillomavirus (HPV) vaccines show high efficacy in preventing cervical cancer and genital warts. Widespread vaccination could eventually eliminate the need for cervical cancer screening.

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • Human papillomavirus (HPV) infection, particularly HPV 16 and 18, is the primary cause of cervical cancer.
  • Prophylactic HPV vaccines target specific HPV types responsible for cervical cancer and genital warts.

Purpose of the Study:

  • To evaluate the efficacy of prophylactic HPV vaccines in preventing persistent HPV infection and cervical intraepithelial neoplasia (CIN).
  • To assess the potential of HPV vaccination to reduce cervical cancer incidence and the need for screening.

Main Methods:

  • Clinical trials of two prophylactic HPV vaccines (Gardasil and Cervarix) were reviewed.
  • Efficacy data for protection against HPV types 6, 11, 16, and 18 were analyzed up to five years post-vaccination.

Related Experiment Videos

Main Results:

  • Vaccines demonstrated 100% efficacy against persistent HPV infection and CIN development.
  • Gardasil offers protection against genital warts and cervical cancer; Cervarix targets cervical cancer alone.
  • Cross-protection against HPV types 31 and 45 suggests broader potential efficacy.

Conclusions:

  • HPV vaccines are highly effective in preventing HPV-related diseases.
  • Widespread vaccination, particularly in young girls, could significantly reduce cervical cancer rates.
  • Ongoing cervical screening remains necessary for unvaccinated generations.